301 related articles for article (PubMed ID: 15199439)
1. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M
Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia].
Oliva J; López-Bastida J; Moreno SG; Mata P; Alonso R
Rev Esp Cardiol; 2009 Jan; 62(1):57-65. PubMed ID: 19150015
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands.
Marang-van de Mheen PJ; ten Asbroek AH; Bonneux L; Bonsel GJ; Klazinga NS
Eur Heart J; 2002 Dec; 23(24):1922-30. PubMed ID: 12473254
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
5. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
[TBL] [Abstract][Full Text] [Related]
6. Cascade genetic screening for familial hypercholesterolemia.
Leren TP
Clin Genet; 2004 Dec; 66(6):483-7. PubMed ID: 15521974
[TBL] [Abstract][Full Text] [Related]
7. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
Chen CX; Hay JW
Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
[TBL] [Abstract][Full Text] [Related]
10. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
[TBL] [Abstract][Full Text] [Related]
11. [Genetic screening for familial hypercholesterolemia in 1992-1997: primarily younger patients in the care of family physicians].
ten Asbroek AH; van Lunsen S; Marang-van de Mheen PJ; Gunning-Schepers LJ
Ned Tijdschr Geneeskd; 2000 Jan; 144(3):125-9. PubMed ID: 10674119
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of statins in coronary heart disease.
Franco OH; Peeters A; Looman CW; Bonneux L
J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419
[TBL] [Abstract][Full Text] [Related]
14. [Is detection and treatment of familial hypercholesterolemia indicated in children?].
Bakker HD; Wiegman A; Defesche JC; Kastelein JJ
Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2548-51. PubMed ID: 9555154
[TBL] [Abstract][Full Text] [Related]
15. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA
Health Technol Assess; 2000; 4(29):1-123. PubMed ID: 11109029
[TBL] [Abstract][Full Text] [Related]
16. White matter hyperintensities on T2-weighted MRI images among DNA-verified older familial hypercholesterolemia patients.
Hyttinen L; Autti T; Rauma S; Soljanlahti S; Vuorio AF; Strandberg TE
Acta Radiol; 2009 Apr; 50(3):320-6. PubMed ID: 19229678
[TBL] [Abstract][Full Text] [Related]
17. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening.
Leren TP; Finborud TH; Manshaus TE; Ose L; Berge KE
Community Genet; 2008; 11(1):26-35. PubMed ID: 18196915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
